The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Links

 

Gene Review

Apoc3  -  apolipoprotein C-III

Mus musculus

Synonyms: Apo-CIII, ApoC-III, Apolipoprotein C-III, Apolipoprotein C3, apo-CIII, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Apoc3

  • Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia [1].
  • 4. Remarkably, LDL modified by oxidation, treatment with phospholipase A2, or enrichment with apolipoprotein CIII, which are modifications associated with increased atherogenesis, is hydrolyzed readily by S-SMase at pH 7 [2].
  • Moreover, the administration of fenofibrate not only resulted in liver hypertrophy and reduction in hepatic lipid accumulation, but also regulated the transcriptional expression of PPARalpha target genes, such as hepatic acyl-coenzyme A (CoA) oxidase and apolipoprotein C-III (apoC-III) [3].
 

High impact information on Apoc3

 

Chemical compound and disease context of Apoc3

 

Biological context of Apoc3

 

Anatomical context of Apoc3

 

Associations of Apoc3 with chemical compounds

  • These data indicate that ApoC-III modulates the catabolism of triglyceride-rich lipoproteins and plays a role in the postprandial management of triglycerides [1].
  • Similar to apoE(+/+) apoC3(-/-) mice, apoE(-/-)apoC3(-/-) mice exhibited a marked reduction in VLDL cholesterol and TG, indicating that the mechanism(s) by which apoC-III deficiency exerts its lipid-lowering effect act independent of apoE [10].
  • In addition, administration of fenofibrate reduced serum lipids and hepatic apolipoprotein C-III mRNA while increasing the mRNA of acyl-CoA oxidase in both groups of mice, however, these effects were more pronounced in OVX LDLR-null mice [14].
  • Association between the SstI polymorphism of the apolipoprotein C-III gene, glucose intolerance and cardiovascular risk in renal transplant recipients [15].
 

Physical interactions of Apoc3

 

Other interactions of Apoc3

  • Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species [9].

References

  1. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. Maeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S.H., Osada, J. J. Biol. Chem. (1994) [Pubmed]
  2. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. Schissel, S.L., Jiang, X., Tweedie-Hardman, J., Jeong, T., Camejo, E.H., Najib, J., Rapp, J.H., Williams, K.J., Tabas, I. J. Biol. Chem. (1998) [Pubmed]
  3. Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Jeong, S., Kim, M., Han, M., Lee, H., Ahn, J., Kim, M., Song, Y.H., Shin, C., Nam, K.H., Kim, T.W., Oh, G.T., Yoon, M. Metab. Clin. Exp. (2004) [Pubmed]
  4. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. Li, W.W., Dammerman, M.M., Smith, J.D., Metzger, S., Breslow, J.L., Leff, T. J. Clin. Invest. (1995) [Pubmed]
  5. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Claudel, T., Inoue, Y., Barbier, O., Duran-Sandoval, D., Kosykh, V., Fruchart, J., Fruchart, J.C., Gonzalez, F.J., Staels, B. Gastroenterology (2003) [Pubmed]
  6. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Juntti-Berggren, L., Refai, E., Appelskog, I., Andersson, M., Imreh, G., Dekki, N., Uhles, S., Yu, L., Griffiths, W.J., Zaitsev, S., Leibiger, I., Yang, S.N., Olivecrona, G., Jörnvall, H., Berggren, P.O. Proc. Natl. Acad. Sci. U.S.A. (2004) [Pubmed]
  7. The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein C-III enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene. Le Beyec, J., Chauffeton, V., Kan, H.Y., Janvier, P.L., Cywiner-Golenzer, C., Chatelet, F.P., Kalopissis, A.D., Zannis, V., Chambaz, J., Pinçon-Raymond, M., Cardot, P. J. Biol. Chem. (1999) [Pubmed]
  8. Apolipoprotein CIII deficiency prevents the development of hypertriglyceridemia in streptozotocin-induced diabetic mice. Takahashi, T., Hirano, T., Okada, K., Adachi, M. Metab. Clin. Exp. (2003) [Pubmed]
  9. Characterization of the mouse apolipoprotein Apoa-1/Apoc-3 gene locus: genomic, mRNA, and protein sequences with comparisons to other species. Januzzi, J.L., Azrolan, N., O'Connell, A., Aalto-Setälä, K., Breslow, J.L. Genomics (1992) [Pubmed]
  10. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. Jong, M.C., Rensen, P.C., Dahlmans, V.E., van der Boom, H., van Berkel, T.J., Havekes, L.M. J. Lipid Res. (2001) [Pubmed]
  11. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F.W., Sacks, F.M. Circulation (2006) [Pubmed]
  12. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression. Gerritsen, G., Rensen, P.C., Kypreos, K.E., Zannis, V.I., Havekes, L.M., Willems van Dijk, K. J. Lipid Res. (2005) [Pubmed]
  13. Apolipoprotein C-III can specifically bind to hepatic plasma membranes. Fang, D.Z., Liu, B.W. Mol. Cell. Biochem. (2000) [Pubmed]
  14. Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice. Yoon, M., Jeong, S., Lee, H., Han, M., Kang, J.H., Kim, E.Y., Kim, M., Oh, G.T. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
  15. Association between the SstI polymorphism of the apolipoprotein C-III gene, glucose intolerance and cardiovascular risk in renal transplant recipients. Rodrigo, E., González-Lamuño, D., Ruiz, J.C., Fresnedo, G.F., Isla, D., Cotorruelo, J.G., Zubimendi, J.A., de Francisco, A.L., Garcia-Fuentes, M., Arias, M. Transplant. Proc. (2002) [Pubmed]
  16. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. Palmer, C.N., Hsu, M.H., Muerhoff, A.S., Griffin, K.J., Johnson, E.F. J. Biol. Chem. (1994) [Pubmed]
 
WikiGenes - Universities